We are live on ! Find out more
SYRS

Syros Pharmaceuticals, Inc. Common Stock
SYRS

Delisted

SYRS was delisted on the 19th of March, 2025.

Back to rankings

70 hedge funds and large institutions have $291M invested in Syros Pharmaceuticals, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 31 increasing their positions, 14 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

121% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 14

89% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 9

13% more funds holding

Funds holding: 62 → 70 (+8)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

35% less capital invested

Capital invested by funds: $446M → $291M (-$156M)

Holders
70
Holders Change
+8
Holders Change %
+12.9%
% of All Funds
1.38%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
17
Increased
31
Reduced
14
Closed
9
Calls
$956K
Puts
–
Net Calls
+$956K
Net Calls Change
-$592K

Top Buyers

Rank Fund Capital Flow
1
AIM
ARK Investment Management
Florida
+$7.54M
2
JP Morgan Chase
JP Morgan Chase
New York
+$3.19M
3
Millennium Management
Millennium Management
New York
+$3.07M
4
SCM
Sio Capital Management
New York
+$2.72M
5
NAMA
Nikko Asset Management Americas
New York
+$2.07M

Top Sellers

Rank Fund Capital Flow
1
RG
Redmile Group
California
-$22.3M
2
6CM
683 Capital Management
New York
-$4.46M
3
AVM
Arch Venture Management
Illinois
-$3.28M
4
CS
Candriam SCA
Luxembourg
-$1.75M
5
BBA
Baker Bros. Advisors
New York
-$1.73M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Advisers
26
Two Sigma Advisers
New York
$729K +$640K +10,550 New
California State Teachers Retirement System (CalSTRS)
27
California State Teachers Retirement System (CalSTRS)
California
$373K +$4.06K +67 +1%
State of Wisconsin Investment Board
28
State of Wisconsin Investment Board
Wisconsin
$359K – – –
Goldman Sachs
29
Goldman Sachs
New York
$357K +$91.9K +1,515 +42%
Morgan Stanley
30
Morgan Stanley
New York
$355K +$250K +4,129 +410%
Jacobs Levy Equity Management
31
Jacobs Levy Equity Management
New Jersey
$312K +$274K +4,522 New
Squarepoint
32
Squarepoint
New York
$311K +$273K +4,500 New
UBS Group
33
UBS Group
Switzerland
$307K +$133K +2,185 +97%
T. Rowe Price Associates
34
T. Rowe Price Associates
Maryland
$294K -$210K -3,466 -45%
RhumbLine Advisers
35
RhumbLine Advisers
Massachusetts
$272K +$2.79K +46 +1%
PP
36
PDT Partners
New York
$267K +$137K +2,257 +141%
ECM
37
ExodusPoint Capital Management
New York
$254K +$223K +3,678 New
Barclays
38
Barclays
United Kingdom
$245K +$107K +1,768 +99%
BCM
39
Bridgeway Capital Management
Texas
$230K – – –
AG
40
Algert Global
California
$223K +$196K +3,229 New
New York State Common Retirement Fund
41
New York State Common Retirement Fund
New York
$215K -$25.5K -420 -12%
AllianceBernstein
42
AllianceBernstein
Tennessee
$211K +$8.49K +140 +5%
ARTA
43
A.R.T. Advisors
New York
$204K +$179K +2,946 New
California Public Employees Retirement System
44
California Public Employees Retirement System
California
$198K +$174K +2,870 New
GCP
45
GSA Capital Partners
United Kingdom
$192K +$168K +2,776 New
Acadian Asset Management
46
Acadian Asset Management
Massachusetts
$182K +$160K +2,641 New
Wells Fargo
47
Wells Fargo
California
$181K -$8.8K -145 -5%
AIG
48
American International Group
New York
$150K -$1.09K -18 -0.8%
Two Sigma Investments
49
Two Sigma Investments
New York
$150K +$132K +2,170 New
Manulife (Manufacturers Life Insurance)
50
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$149K -$6.55K -108 -5%
1
2
3 4

SYRS Hedge Fund Activity: Q4 2019 in Review

70 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q4 2019, worth a combined $291M — down 35% from $446M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new SYRS positions and 9 closed out — a net gain of 8 holders — while 31 added to existing stakes and 14 trimmed.

The largest buyer was ARK Investment Management, adding an estimated $7.54M. The largest seller was Redmile Group, cutting an estimated $22.3M.

  • 70 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q4 2019, up from 62 in Q3 2019.
  • Funds reported $291M of Syros Pharmaceuticals, Inc. Common Stock stock for Q4 2019, down 35% quarter-over-quarter.
  • 17 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q4 2019 and 9 closed out, a net change of +8 holders.
  • The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q4 2019 was ARK Investment Management, an estimated $7.54M added.
  • The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q4 2019 was Redmile Group, an estimated $22.3M sold.

Based on aggregated 13F filings for Q4 2019.